Notably, T3-like binding to THR-α of THR-β agonist has been demonstrated to exert deleterious effects on the skeletal and cardiac systems, which represents a significant impediment to its utilization in the treatment of obesity and MASH. The gene discussed is THRA; the disease is obesity disorder.